Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells

Wang,Huan; Zhu,Xiaoli; Huang,Jing; Chen,Pingsheng; Han,Shuhua; Yan,Xing

doi:10.3892/ol.2016.4276

Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells

Authors:
- Huan Wang
- Xiaoli Zhu
- Jing Huang
- Pingsheng Chen
- Shuhua Han
- Xing Yan
View Affiliations

Affiliations: Department of Respiratory Medicine, The Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Pathology, Medical School of Southeast University, Nanjing, Jiangsu 210009, P.R. China
Published online on: February 24, 2016 https://doi.org/10.3892/ol.2016.4276
Pages: 2566-2572

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (DDP) has been one of the most widely used chemotherapy drugs for advanced non-small cell lung cancer. However, the increase in the number of DDP-resistant cancer cells has become a major impediment in the clinical management of cancer. In the present study, for the first time, the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay was used to demonstrate that nedaplatin (NDP) could have a stronger inhibitory effect than DDP alone in DDP‑resistant A549 (A549DDP) cells and that it could attenuate the resistance of these cells. Additionally, flow cytometry analysis showed that the apoptosis rate of these resistant cells when exposed to NDP was markedly increased and the number of cells in the G2 stage of the cell cycle was significantly increased. Furthermore, western blot analysis indicated that NDP decreased the protein expression of P‑glycoprotein, tumor protein p53 and B‑cell lymphoma 2, and increased the expression of Bcl‑2‑associated X protein, all of which could possibly improve the NDP intracellular drug concentration and promote cell apoptosis. These observations suggested that NDP could have higher efficacy in DDP-resistant lung cancer cells, and further studies applying more detailed analyses are warranted to elucidate the mechanism(s) behind this effect.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Azzoli CG, Temin S and Giaccone G: 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 8:63–66. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ettinger DS, Akerley W, Borqhaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 11:645–653. 2013.PubMed/NCBI
4	Rigas JR: Taxane-platinum combinations in advanced non-small cell lung cancer: A review. Oncologist. 9(Suppl 2): S16–S23. 2004. View Article : Google Scholar
5	Davis A, Tinker AV and Friedlander M: ‘Platinum resistant’ ovarian cancer: What is it, who to treat and how to measure benefit? Gynecol Oncol. 133:624–631. 2014. View Article : Google Scholar : PubMed/NCBI
6	Torigoe T, Izumi H, Ishiguchi H, et al: Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents. 5:15–27. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gao L, Liu G, Ma J, Wang X, Wang F, Wang H and Sun J: Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells. Colloids Surf B Biointerfaces. 117:122–127. 2014. View Article : Google Scholar : PubMed/NCBI
8	Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ and Richardson DR: P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem. 288:31761–31771. 2013. View Article : Google Scholar : PubMed/NCBI
9	Cavallo F, Feldman DR and Barchi M: Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. Int J Dev Biol. 57:273–280. 2013. View Article : Google Scholar : PubMed/NCBI
10	Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR and BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
11	Wang G, Reed E and Li QQ: Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep. 12:955–965. 2004.PubMed/NCBI
12	Ota K: Nedaplatin. Gan To Kagaku Ryoho. 23:379–387. 1996.(In Japanese). PubMed/NCBI
13	Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z and Wang D: Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 4:1017–1021. 2009. View Article : Google Scholar : PubMed/NCBI
14	Li CH, Liu MY, Liu W, Li DD and Cai L: Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev. 15:731–736. 2014. View Article : Google Scholar : PubMed/NCBI
15	Sharom FJ: Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: Its role in modulating protein function. Front Oncol. 4:412014. View Article : Google Scholar : PubMed/NCBI
16	Fu D: Where is it and how does it get There-intracellular localization and traffic of P-glycoprotein. Front Oncol. 3:3212013. View Article : Google Scholar : PubMed/NCBI
17	Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP and Deb S: Gain-of-function activity of mutant p53 in lung cancer through up-regulation of receptor protein tyrosine kinase axl. Genes Cancer. 3:491–502. 2012. View Article : Google Scholar : PubMed/NCBI
18	Wu ZZ, Sun NK and Chao CC: Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis. J Cell Physiol. 226:2415–2428. 2011. View Article : Google Scholar : PubMed/NCBI
19	Bazzi H and Anderson KV: Acentriolar mitosis activates a p53-dependent apoptosis pathway in the mouse embryo. Proc Natl Acad Sci USA. 111:E1491–E1500. 2014. View Article : Google Scholar : PubMed/NCBI
20	Oren M and Rotter V: Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2:a0011072010. View Article : Google Scholar : PubMed/NCBI
21	Perrone F, Bossi P, Cortelazzi B, Locati L, Quattrone P, Pierotti MA, Pilotti S and Licitra L: TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol. 28:761–766. 2010. View Article : Google Scholar : PubMed/NCBI
22	Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G and Sacchi A: Mutant p53 gain of function: Reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 25:304–309. 2006.PubMed/NCBI
23	Tian B, Liu J, Liu B, Dong Y, Liu J, Song Y and Sun Z: p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line. J Cell Physiol. 226:3433–3441. 2011. View Article : Google Scholar : PubMed/NCBI
24	Cuddihy AR, Jalali F, Coackley C and Bristow RG: WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Mol Cancer Ther. 7:980–992. 2008. View Article : Google Scholar : PubMed/NCBI
25	Chung SK, Zhu S, Xu Y and Fu X: Functional analysis of the acetylation of human p53 in DNA damage responses. Protein Cell. 5:544–551. 2014. View Article : Google Scholar : PubMed/NCBI
26	Podolski-Renić A, Jadranin M, Stanković T, Banković J, Stojković S, Chiourea M, Aljančić I, Vajs V, Tešević V, Ruždijić S, et al: Molecular and cytogenetic changes in multi-drug resistant cancer cells and their influence on new compounds testing. Cancer Chemother Pharmacol. 72:683–697. 2013. View Article : Google Scholar : PubMed/NCBI
27	Pore MM, Hiltermann TJ and Kruyt FA: Targeting apoptosis pathways in lung cancer. Cancer Lett. 332:359–368. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kumar Biswas S, Huang J, Persaud S and Basu A: Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther. 3:327–334. 2004.PubMed/NCBI
29	Gumulec J, Balvan J, Sztalmachova M, Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K, Ruttkay-Nedecky B, Babula P, et al: Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle. Int J Oncol. 44:923–933. 2014.PubMed/NCBI
30	Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N and Matsubara H: A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma. Hepatogastroenterology. 59:2095–2098. 2012.PubMed/NCBI
31	Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, et al: Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil and radiation. Int J Clin Oncol. 11:454–460. 2006. View Article : Google Scholar : PubMed/NCBI